Vaxess adds Fenel Eloi to Board of Directors
Vaxess Technologies, a Cambridge, Massachusetts life sciences company developing a shelf-stable, sustained-release vaccine patch, has announced that Fenel Eloi has joined its board of directors.
Fenel Eloi brings to Vaxess more than 30 years experience as a leader in the life sciences industry. He is currently managing partner of P&M capital partners, a private angel investment firm. Previously, Eloi was the Chief Financial Officer and then Chief Operating Officer of Cell Signaling Technology, a privately held life sciences company, where he oversaw significant growth of the business over a period of 12 years and provided leadership in the transformation of the company to a global operation.
Prior to that, Eloi was the Chief Operating Officer and Chief Financial Officer of Interleukin Genetics, Inc., a formerly NASDAQ-listed diagnostic company. Additional positions included Chief Financial Officer at LifeCell Corp and Genome Therapeutics Corp, both formerly NASDAQ-listed companies.
In addition to his board role with Vaxess, Eloi currently serves on the board of directors of MitoTherapeutix, a privately held drug development biotech company; Ultivue, Inc., a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing; 908 Devices, Inc., a publicly-traded mass spectrometry device company; and VIC, a technology venture development company for high impact life science ventures. Eloi previously served on the board of Cell Signaling Technology, Inc., a reagents company, and BioHelix Corporation, a diagnostics company.
Eloi is joining Vaxess’ Board of Directors during a time of ‘significant growth’ for the company and its Mimix vaccine patch. Recently, Vaxess announced $27 million in Series B funding, launched a phase 1 trial for the H1 influenza vaccine delivered by VX-103 (a MIMIX Array Patch System), and announced a series of leadership additions.
Vaxess has received grant and venture capital funding from groups such as RA Capital, The Engine, BARDA, DARPA, NIH, NSF and the Gates Foundation.
